Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
0.1049
+0.0049 (4.90%)
NASDAQ · Last Trade: Jul 29th, 6:19 PM EDT
Detailed Quote
Previous Close
0.1000
Open
0.1200
Bid
0.1197
Ask
0.1200
Day's Range
0.0997 - 0.1200
52 Week Range
0.0975 - 1.480
Volume
55,910,664
Market Cap
161.09M
PE Ratio (TTM)
-2.098
EPS (TTM)
-0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
7,163,146
Chart
About Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer. The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies. Read More
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Get a pulse on the US markets on Monday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
